Autoreactive CD4 + T cells are involved in the pathogenesis of many autoimmune diseases, but the antigens that stimulate their responses have been difficult to identify and in most cases are not well defined. In the nonobese diabetic (NOD) mouse model of type 1 diabetes, we have identified the peptide WE14 from chromogranin A (ChgA) as the antigen for highly diabetogenic CD4 + T cell clones. Peptide truncation and extension analysis shows that WE14 bound to the NOD mouse major histocompatibility complex class II molecule I-A g7 in an atypical manner, occupying only the carboxy-terminal half of the I-A g7 peptide-binding groove. This finding extends the list of T cell antigens in type 1 diabetes and supports the idea that autoreactive T cells respond to unusually presented self peptides.
The self antigen targets in many autoimmune diseases for both humans and mice have been identified by the presence of serum autoantibodies. Examples are DNA and chromatin in systemic lupus erythematosis, immunoglobulin in rheumatoid arthritis, and insulin in type I diabetes. Most autoimmune diseases also involve autoreactive CD4 + T cells that not only are required for autoantibody production but also can be pathogenic, as in type 1 diabetes. In some instances, such as insulin, epitopes for autoreactive CD4 + T cells have been found in the same proteins targeted by autoantibodies. In general, however, identification of the relevant T cell autoantigen epitopes has been much more difficult and the targets of autoreactive T cells have remained largely undefined.
The pathogenic CD4 + T cells that arise in the nonobese diabetic (NOD) mouse model of type 1 diabetes provide a striking example. Over the years, many laboratories have identified CD4 + T cell clones in NOD mice that are reactive to pancreatic antigens in vitro and that also cause or accelerate diabetes in various types of in vivo experiments. Some of these clones have turned out to be specific for insulin epitopes, but the antigenic targets of other highly pathogenic CD4 + T cell clones are unknown. The most extensively studied of these are the BDC clones, which include BDC-2.5, isolated from the spleens and lymph nodes of diabetic NOD mice 1, 2 . The BDC clones are not responsive to insulin but respond in vitro to pancreatic islet cells or cell extracts from beta-cell adenomas presented in the context of the major histocompatibility complex (MHC) antigen I-A g7 (refs. 3,4) . Polymorphisms unique to the allele encoding this MHC class II molecule are very strongly associated with disease 5, 6 . The highly pathogenic nature of these clones has been demonstrated by adoptive transfer into young NOD mice, in which they greatly accelerate the development of type 1 diabetes 2, 7 . T cells from BDC T cell antigen receptor (TCR)-transgenic mice are similarly aggressive in vivo 8, 9 . In addition, the introduction of the genes encoding BDCspecific TCRs into T cell-deficient NOD.scid mice (retrogenic mice) rapidly induces type 1 diabetes 10 . Published studies have suggested that most of these clones react to a common pancreatic antigen 3, 4 , but despite many efforts, this antigen has never been identified.
Here we identify chromogranin A (ChgA) as the source of the antigen for BDC-2.5 and two other clones, based on mass-spectrometric analysis of biochemically purified antigenic fractions from an islet beta-cell tumor and on the demonstration that this antigen was missing from the pancreatic islet cells from Chga −/− mice. Peptide antigen mimotopes for these T cells, identified here and in published studies 11, 12 , shared a common amino acid motif in the predicted portion of the peptides at positions 5-9 (p5-p9), (WX(R/K)M(D/E), where 'X' indicates any amino acid, '(R/K)' indicates arginine or lysine, and '(D/E)' indicates aspartic acid or glutamic acid), which suggested that the ChgA amino acid sequence 358-371 (EDKRWSRMD; underlining indicates the relevant common motif) was the probable antigenic epitope. Unexpectedly, peptides containing this sequence did not activate the T cells, but the clones were activated by an overlapping peptide, WE14 (amino acids 359-372; WSRMDQLAKELTAE), a natural cleavage product of ChgA 13 . This finding was unexpected, because despite the presence of the antigen motif, the stimulating WE14 peptide lacked the amino (N)-terminal amino acids that would occupy positions p1-p4 of the I-A g7 peptide-binding groove and are normally important for stable MHC class II binding. Binding studies suggested that the nine carboxy (C)-terminal amino acids of WE14 make up for this loss by interacting with I-A g7 at a site outside the normal binding groove.
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RESULTS
Proteomic identification of ChgA
Our first approach to identify candidate antigens for the BDC clones was through biochemical separation and proteomic analysis of antigens in a partially purified protein preparation from the secretory granules of a beta-cell adenoma tumor 14 . It has been shown before that the relevant antigen is present in these cells and that several of the BDC clones react with the same granule fraction 3, 4 . We further purified the antigen with a combination of size-exclusion chromatography (SEC) and ion-exchange chromatography (IEX), tracking the antigen through the response of the prototypic T cell clone BDC-2.5 ( Fig. 1a,b) . The final highly purified fractions also stimulated two other T cell clones, BDC-10.1 and BDC-5.10.3 (data not shown). Each step of separation had a different degree of purification ( Table 1) ; silver staining of an SDS-PAGE gel showed the protein content of the combined antigen-containing SEC fractions (Fig. 1c, lane 2) and peak antigenic fractions from IEX (Fig. 1c, lanes 3-7) .
To identify the proteins present in the IEX fractions containing the antigenic activity, we analyzed tryptic digestions from each fraction by mass spectrometry. We sequenced the resulting peptides and matched them to proteins by searching the Swiss-Prot protein database with the database search program Spectrum Mill. We identified a total of 21 proteins in fractions 19-23 with this technique, and the spectral intensities indicated the relative abundance of individual proteins identified in each fraction (Fig. 2a) . A comparison of spectral intensities with the corresponding antigenicity in each fraction resulted in a list of potential antigen candidates, including secretogranins 1 and 2, insulin-like growth factor II and ChgA (mass spectra and matching sequence for two peptides, Fig. 2b,c) . We obtained nearly identical results in five independent experiments, with the exception of insulinlike growth factor, which we only identified in one experiment. Overall, we confidently identified six ChgA peptides mapping to the more C-terminal portion of the protein (amino acids 233-463) in highly antigenic fractions, with four peptides being reproducibly detected in three experiments (Fig. 2d) . The predicted molecular weight of this potentially truncated ChgA protein (amino acids 235-463) was approximately 26 kilodaltons, which was consistent with the results of SEC. On the basis of these results and the close correlation of antigenicity with the distribution of ChgA in the fractions, we decided to investigate ChgA further as a candidate antigen.
Islets lacking ChgA do not stimulate the T cell clones
To determine whether ChgA was the source of antigen for the BDC-2.5 T cell clone and the similar BDC-10.1 and BDC-5.10.3 clones, we compared antigen abundance in pancreatic islet cells from Chga −/− and Chga +/+ mice 15 . Although Chga −/− mice are apparently healthy and normal in most respects, they do show some irregularities in terms of islet numbers, size and insulin secretion 16 . Therefore, we included the PD-12.4.4 insulin-reactive clone 17 as a control for any global deficiencies in the Chga −/− mice in islet beta-cell or granule formation. We cultured the T cell clones with I-A g7 antigen-presenting cells and various numbers of islet cells from the Chga −/− or Chga +/+ mice as a source of antigen; we used the beta-cell tumor antigen preparation as a positive control. We used the production of interferon-γ (IFN-γ) as a measure of T cell activation. All four T cell clones responded well to the control antigen (Fig. 3a) . The PD-12.4.4 insulin-reactive clone responded equally well to islet cells from either Chga +/+ or Chga −/− mice (Fig. 3b,c) , which suggested equivalent insulin abundance in individual islet beta cells from either source. The three BDC clones also responded well to Chga +/+ islet cells but not at all to islet cells obtained from Chga −/− mice (Fig. 3b,c) . These results confirm ChgA as the source of the antigen for these BDC T cell clones.
Peptide mimotope for three diabetogenic T cell clones
In a parallel set of studies, we identified a previously unknown peptide mimotope for the three BDC clones in a library of peptides covalently bound to I-A g7 and displayed on the surface of insect cells through baculovirus, as described before 18, 19 . On the basis of studies of crystal structures of peptides bound to I-A g7 (refs. 20,21) , the peptide amino acids in the baculovirus-encoded library (~1 × 10 7 independent clones) were minimally varied at the four main peptide-I-A g7 -binding positions as follows: p1 (arginine or leucine), p4 (leucine or valine), p6 (leucine or valine) Purification results, presented as applied activity (starting amount of antigen (in antigen units) purified by various steps (Procedure)); activity yield (amount of antigen obtained after each purification step); and specific activity (activity yield divided by total protein).
NA, not applicable and p9 (glycine or glutamic acid). The amino acids at positions p-1, p2, p3, p5, p7 and p8 were fully randomized to all 20 amino acids. We infected insect cells with the library at a multiplicity of infection of <1 so that most infected cells expressed a single member of the library. We isolated by flow cytometry the few infected cells expressing a peptide-I-A g7 combination able to bind a fluorescent, soluble multimeric version of BDC-2.5 TCR (Methods; Fig. 4a , left). We used positive cells to create a new enriched viral stock. We did this experimental cycle twice more; this produced a highly enriched population of viruses that expressed peptide-I-A g7
combinations, most of which bound the BDC-2.5 TCR (Fig. 4a, middle) . We retested cloned viruses from this enriched population for binding to the BDC-2.5 TCR. We sequenced the viral DNA for all TCR-binding clones and found that it encoded a single peptide sequence, SRLGLWVRME (pS3; Fig. 4a , right). We tested the ability of T cell hybridomas bearing TCRs from the BCD-2.5, BDC-10.1 or BDC-5.10.3 T cell clone to recognize the covalent pS3-I-A g7 complex using insect cells expressing the costimulatory molecule CD80 and the cell adhesion molecule ICAM-1 as artificial antigen-presenting cells 18, 19 (Fig. 4b) 219  145  134  108  108  80  72  67  58  57  56  44  41  41  39  28  35  35  21 A r t i c l e s were maximally activated by the pS3 mimotope, which bolstered the idea that all three T cells were reactive to the same self antigen and that the pS3 sequence might resemble that of the natural antigen. Two published studies have used the technique of positionalscanning peptide libraries to identify antigen mimotopes for one or more of these three BDC T cell clones 11, 12 (Fig. 4c) . A striking feature of these mimotopes and pS3 was the common WX(R/K)M(D/E) motif in amino acids at positions p5-p9 of the peptides. Previous searches of databases with these other mimotope sequences failed to identify the natural source of the antigen 11, 12 . However, examination of the ChgA sequence identified this motif in the C-terminal portion of protein and suggested that the probable core peptide epitope (p-1 to p9) in ChgA was amino acids 353-362 (WEDKRWSRMD). We incorporated a DNA sequence encoding this peptide into the baculovirus I-A g7 construct and used the resulting virus to infect insect cells expressing CD80 and ICAM-1. Cells infected with a covalent complex of hen egg lysozyme peptide and I-A g7 (pHEL-I-A g7 ) or pS3-I-A g7 served as a negative or positive control, respectively. We tested these cells for activation of the BDC-2.5 and BDC-10.1 T cell clones by measuring production of IFN-γ (Fig. 4d) . As expected, cells expressing pHEL-I-A g7 did not activate either clone, and the pS3-I-A g7 cells strongly activated both clones. Unexpectedly, the cells expressing a covalent complex of the ChgA peptide and I-A g7 failed to stimulate either T cell clone.
As the sequence WEDKRWSRMD represented the only sequence in ChgA with any homology to the antigen mimotopes, we examined the mimotope sequences more closely (Fig. 4c) . Although the N-terminal sequences of the mimotopes (p-1 to p4 or p1 to p4) varied considerably, they all had a small uncharged amino acid at p3 (glycine, alanine or proline). In contrast, the ChgA peptide had a large, positively charged amino acid (lysine) at this position. We postulated that this lysine could have been sterically blocking epitope recognition by T cells. This idea was strengthened by a mutational study of this position in the pS3 mimotope in which we tested variants of pS3 with substitution of the glycine at p3 with many other amino acids (Fig. 4e) . Single substitutions with amino acids with small side chains (alanine, serine or threonine) preserved the ability of the mimotope to stimulate all three BDC T cell hybridomas. However, changing this amino acid to lysine, the p3 amino acid of the ChgA peptide, or to several other amino acids with large side chains eliminated the activation of all three BDC T cell clones.
Identification of a natural antigenic epitope from ChgA
Our results suggested that the N-terminal part of the ChgA peptide interferes with T cell recognition, which led us to consider the naturally processed ChgA-derived peptide WE14 (WSRMDQLAKELTAE) 13 . This peptide lacked the first five amino acids (p-1 to p4) of the previously tested ChgA peptide (Fig. 4d) but retained the common mimotope motif, with additional amino acids present at the carboxyl terminus (Fig. 5a) . We predicted this peptide would bind poorly to I-A g7 because placement of the WSRMD pentapeptide in the p5-p9 position would only partially fill the peptide-binding groove, eliminating many of the usually conserved interactions between MHC class II molecules and peptide involving positions p-1 to p4. We tested the ability of a soluble synthetic version of WE14 to activate the three BDC T cell clones, comparing it with the pS3 mimotope and the control beta-cell tumor antigen preparation (Fig. 5b) . The pS3 mimotope potently stimulated all three BDC clones maximally at all concentrations tested. All three clones also responded to the beta-cell antigen preparation. The WE14 peptide also stimulated all three BDC clones, which confirmed the idea that elimination of the ChgA amino acids predicted to occupy positions p1-p4 in the I-A g7 -binding groove was necessary for T cell recognition. As a negative control, we tested the insulin-reactive T cell clone PD-12.4.4 and its insulin-derived peptide epitope, B:9-23 (ref. 17) . As expected, PD-12.4.4 responded to the insulin peptide and beta-cell antigen preparation but did not respond to pS3 or either ChgA peptide. The synthetic WE14 peptide was also considerably less potent than the beta-cell antigen preparation, which suggested that the natural version of this peptide may be subject in vivo to some alternative form of processing or to post-translational modification.
To confirm the unique binding register of the WE14 peptide, we did experiments with a series of peptides that were N-terminal extensions and/or C-terminal deletions of WE14 (Fig. 6) . We evaluated the ability of the peptides to stimulate the BDC-2.5 T cell clone (Fig. 6a) or to bind to I-A g7 , as judged by inhibition of binding of the biotinylated control peptide pHEL (Fig. 6b) . We used the pS3 mimotope as the positive control peptide and an irrelevant peptide from moth cytochrome c as a negative control. We used the data from these experiments (Fig. 6a,b) to calculate the stimulatory or binding capacity of the test peptides relative to that of WE14 (Fig. 6c) .
Sequential truncation of WE14 (WL11, WA8 and WD5) from the carboxyl terminus resulted in decreasing stimulatory activity (Fig. 6a,c) . The shortest peptide (WD5), which contained only the WX(R/K)M(E/D) motif, lacked any stimulatory activity. The detrimental effect of these truncations was even more pronounced in the I-A g7 -binding assay (Fig. 6b,c) . WE14 bound to I-A g7 , although not nearly as well as the pS3 mimotope did. However, truncation of as few as three C-terminal amino acids from WE14 (WL11) resulted in binding indistinguishable from that of the negative control peptide. These data indicate that the C-terminal nine amino acids of WE14 were required for optimal binding and stimulation by the peptide. 
A r t i c l e s
Extension of the WE14 or WD5 peptide at the N terminus was also informative. Extending WE14 by four amino acids (EE18) had no effect on I-A g7 binding (Fig. 6b,c) but eliminated the BDC-2.5 response (Fig. 6a,c) , consistent with the idea that additional N-terminal amino acids are incompatible with T cell recognition. Likewise, extending the WD5 peptide by the same four amino acids (ED9) also produced a peptide that failed to stimulate BDC-2.5 (Fig. 6a,c) . We obtained similar results with extensions of WD5 by one amino acid (RD6), two amino acids (KD7) or three amino acids (DD8; data not shown). Unexpectedly, however, the ED9 peptide, despite its length, did not bind to I-A g7 (Fig. 6b,c) . That result, and the finding that EE18 bound to I-A g7 no better than WE14 itself did, suggested that these four amino acids were unable to fill the p1-p4 portion of I-A g7 -binding groove properly, most probably because of a problem with the p4 arginine present at that anchor position. The simplest interpretation of our results is that WE14 uses an unusual means of binding to I-A g7 via interaction of its C-terminal nine amino acids with a site outside the normal I-A g7 -binding groove.
DISCUSSION
The BDC CD4 + T cell clones are highly active in the acceleration or induction of diabetes in vivo. However, their usefulness has been somewhat limited because their antigenic target has remained unknown. We have shown here that the source of the antigen for a main cohort of these clones is ChgA, a protein found in the secretory granules of pancreatic beta cells and other neuroendocrine tissues 22, 23 . We have also shown that WE14, a natural 14-amino acid cleavage product of ChgA 13 , when presented by I-A g7 antigen-presenting cells, activated the ChgA-specific T cell clones in vitro.
In published studies 11, 12 and in our work reported here, various types of peptide libraries were screened to identify peptide mimotopes for one or more of the BDC T cell clones. These libraries were all constructed to contain peptides that would bind well to I-A g7 by placement of suitable anchor residues at the usual p1, p4, p6 and p9 positions of the peptide. Amino acids at other peptide positions were randomized. All of these studies identified mimotopes with similar sequences from p5 to p9 (WX(R/K)M(E/D)), but the sequences varied greatly from p1 to p4.
The identification of WE14 as the active peptide in ChgA was therefore unexpected, as placement of its common motif (WSRMD) in the same positions in the I-A g7 -binding groove predicted by the mimotopes would leave unoccupied any position before p5. In such a case, the peptide would be predicted to bind very poorly, if at all, to I-A g7 , not only because of the lack of the main p1 and p4 anchor amino acids but also because many normally highly conserved hydrogen bonds to the peptide backbone would be missing. Nevertheless, our data have shown that the WE14 peptide bound I-A g7 and potently stimulated all three of the BDC clones. The key to its activity lay in the C-terminal nine amino acids of the peptide, which we found to be critical for binding to I-A g7 . Truncation of even three Cterminal amino acids resulted in much less I-A g7 binding and diminished the T cell response. These data strongly suggest that the carboxyl terminus of WE14 interacts with I-A g7 at a site outside the normal peptide-binding groove, compensating for the lack of the p1-p4 portion of the peptide. Although there are other examples of contributions to MHC class II binding and T cell recognition by peptide by amino acids flanking the binding groove [24] [25] [26] , the requirement for such a long stretch of flanking amino acids is unprecedented, to our knowledge. Furthermore, adding amino acids from the ChgA sequence to the N terminus of the WE14 peptide inhibited, rather than enhanced, peptide presentation and was not able to restore I-A g7 binding or T cell activation in response to the WD5 peptide, which contained the core WE14 WSRMD recognition motif.
We interpret our results as suggesting that the generation of a functional antigen from ChgA requires the removal or alteration of these amino acids to avoid interference with the binding of the TCR to the peptide-I-A g7 complex. This can explain why so many different sequences unrelated to ChgA have been found for the N-terminal part of the antigen mimotopes and why some sequences are recognized by some of the T cell clones but others are not. Depending on the particular TCR, various peptide sequences, but not that of ChgA itself, can fulfill the function of avoiding conflict with the TCR in this region. In addition, as these peptides were all constructed or selected for optimal amino acids at positions p1 and p4 to promote strong I-A g7 binding, they did not require a C-terminal extension like that of WE14, thus providing an explanation for why the various library strategies did not produce mimotopes that suggested WE14 as the source of the antigen.
T cell peptide epitopes that do not fill the MHC class II groove are not unprecedented in autoimmunity. In the mouse model of EAE, the N-terminal peptide of myelin basic protein is a major T cell epitope, but structural studies have concluded that the natural form of this peptide that is recognized by T cells does not fill the beginning of the I-A u -binding groove 27, 28 . In these studies, an active variant of the peptide that filled the rest of the groove with small amino acids was used. In the structure of a TCR bound to this complex, relatively little contact was made to these extra amino acids.
The pS3 peptide mimotope was at least 1,000-fold more potent than the synthetic WE14 peptide in activating the BDC clones. WE14 was also considerably less potent than the antigen preparation from the beta-cell adenoma tumor, despite the fact that ChgA is only one protein species among many. This result may indicate that the naturally processed antigen differs from the synthetic WE14 peptide in some way; for example, because of some form of post-translational modification that improves either the binding of peptide to I-A g7 or the binding of the TCR to the complex. Our mass-spectrometry data leave these possibilities open. For example, whereas published studies have shown the presence of WE14 in the pancreas 29 , we did not identify this peptide directly in the purified antigenic fractions from beta tumor cells. Instead, we found evidence for the presence of the C-terminal portion of ChgA that would contain this peptide, which suggested that further processing or modification in antigen-presenting cells may be required to generate the active epitope.
The idea of post-translational modification of antigens has received considerable attention in studies of T cell-mediated inflammatory disease. For example, in rheumatoid arthritis, citrullination of arginines by peptidylarginine deiminases has been discussed as a possible mechanism for improving the binding of self peptides to HLA-DR4 through the creation of an improved p4 anchor residue 30 . Also, in celiac disease, the conversion of glutamine to glutamic acid in particular gluten peptides by tissue transglutaminase is important in the creation of new T cell epitopes, again by improving peptide binding to the relevant HLA-DQ alleles through changing anchor residues 31, 32 . Both of these enzymes are induced locally by inflammation 33, 34 , which suggests a mechanism by which enhanced antigen presentation can be induced locally in target tissues but not in the thymus, allowing potentially pathogenic T cells to escape thymic deletion. The WE14 peptide has potential amino acids for both of these posttranslational modifications, as well as others, such as lysine hydroxylation.
ChgA is widely expressed in neuroendocrine tissue, and the WE14 cleavage product has been described not only in pancreatic islet beta cells but also in other gastro-entero-pancreatic tissues, such as the adrenal gland 22 . It is unclear why autoimmune attack of these other tissues is not seen in NOD mice. One possibility is that the potency of ChgA as an antigen in the pancreas might be dependent on a pancreas-specific post-translational modification of the relevant peptide, as described above. Alternatively, the selective destruction of beta cells in pancreatic islets has been attributed to their greater sensitivity to inflammatory damage relative to that of other islet cells 35 . Perhaps other neuroendocrine cells are also more resistant to or protected from this type of immune damage.
The question arises of why T cells specific for ChgA exist, given that the widespread expression of this protein might be expected to result in efficient deletion of ChgA-specific T cells during thymic development. In addition to tissue-or inflammation-specific processing or post-translational modifications, another possibility may be poor thymic expression. In a study of regulation of mRNA expression by the autoimmune regulator AIRE in thymus medullary epithelium, Chga mRNA was not detected with or without AIRE 36 , so there may not be sufficient ChgA in the thymus to mediate deletion.
Although caution is always advisable in extending findings in mouse models of autoimmunity to human disease, the available data suggest that the target autoantigens are sometimes the same. For example, considerable overlap between mouse and human autoantigens is thought to be involved in several autoimmune diseases, including multiple sclerosis (myelin basic protein), rheumatoid arthritis (collagen) and lupus erythematosis (DNA and chromatin), as well as type 1 diabetes (insulin). ChgA is highly expressed in human pancreatic cells, and the human form of WE14 peptide has a sequence that is nearly identical to that of the mouse form 37 . Furthermore, the similarity between I-A g7 and the human HLA-DQ alleles associated with type 1 diabetes 38 in the binding and presentation of peptides suggests that WE14 may be presented by MHC class II molecules in humans susceptible to type 1 diabetes. This idea is worth pursuing.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
